阿戈美拉汀治疗女性精神分裂症伴抑郁的临床研究

Clinical Study of Agomelatin in the Treatment of Female Schizophrenia with Depression

目的研究阿戈美拉汀治疗女性精神分裂症伴抑郁的临床疗效,评价其治疗的疗效、起效时间及安全性。方法于2017年5月-2018年6月随机在我院选取精神分裂症伴抑郁的女性患者100例,分为对照组和研究组。对照组单独使用利培酮进行治疗,研究组在对照组的治疗基础上联合阿戈美拉汀进行治疗。观察两组的临床疗效、HAMD-17评分以及治疗的安全性。结果在临床疗效方面研究组总有效率为96.00%而对照组总有效率仅为76.00%;基线时两组患者HAMD-17评分无显著差异,2周末、4周末以及8周末HAMD-17评分研究组患者显著低于对照组患者;在治疗的安全性方面研究组总安全率为88.00%,显著高于对照组总安全率70.00%,差异具有统计学意义(P<0.05)。结论阿戈美拉汀治疗女性精神分裂症伴抑郁的起效时间快、临床疗效显著而且安全性也很高,是一种很好的治疗女性精神分裂症伴抑郁的方法。

Objective To study the clinical efficacy of agomelatine in the treatment of female schizophrenia with depression and to evaluate the efficacy,onset time and safety of the treatment.Methods From May 2017 to June 2018,100 female patients with schizophrenia and depression randomly selected from our hospital were divided into a control group and a research group.The control group was treated with risperidone alone,and the study group was treated with agomelatin on the basis of the treatment of the control group.The clinical efficacy,HAMD-17 score and safety of treatment were observed.Results In the clinical efficacy,the total effective rate of the study group was 96.00%,while that of the control group was only 76.00%.There was no significant difference in the HAMD-17 score between the two groups at the baseline,and the patients in the HAMD-17 score study group were significantly lower than the control group at the 2nd,4th,and 8th weekends.In the safety of treatment,the total safety rate of the study group was 88.00%,which was significantly higher than that of the control group by 70.00%.The difference was statistically significant ( P< 0.05).Conclusion The use of agomelatine in the treatment of female schizophrenia with depression has a fast onset of action,clinical efficacy and high safety.It is a good treatment for female schizophrenia with depression.